Gut microbiome, T cell subsets, and cytokine analysis identify differential biomarkers in tuberculosisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat Was Studied?
This cross-sectional comparative study examined the interplay between the gut microbiome, peripheral T cell subsets, and serum cytokines across stages of tuberculosis (TB). Fecal communities were profiled by 16S rRNA gene sequencing (V3–V4 region, Illumina MiSeq, QIIME2), with predicted metabolic pathway analysis; T cell subsets (CD3+, CD4+, CD8+) were measured by flow cytometry, and a panel of cytokines (including IL-2, IL-4, IL-6, IL-10, IL-17A, IL-12p70, IFN-γ, and TNF-α) by ELISA. The authors integrated these layers and applied logistic regression, random forest modeling, and ROC analysis to identify candidate microbiome-based biomarkers.
Who Was Studied?
The cohort comprised 90 adults enrolled at the 8th Medical Center of the PLA General Hospital in Beijing, China, divided into three equal groups: 30 healthy controls, 30 patients with initial TB (treatment-naive or less than one month of anti-tuberculosis therapy), and 30 patients with recurrent TB (prior treatment exceeding one month or treatment failure). Fecal, serum, and whole-blood specimens were collected. Individuals who had taken probiotics, prebiotics, or antibiotics within the preceding month were excluded.
What Were the Key Findings?
Twenty-six differential taxa and 44 metabolic pathways distinguished the groups, and alpha diversity (Chao1, Shannon, Pielou, observed species) was higher in healthy controls than in recurrent TB patients, while beta diversity showed limited separation. Immunologically, CD4+ cells and the CD4/CD8 ratio were significantly reduced in TB (lowest in recurrent disease), CD8+ and NKT cells were elevated, IL-4 was decreased and IL-6 increased in both TB groups, and IL-10 was elevated in initial TB. Several genera correlated with immune markers, Bacteroides, Bifidobacterium, Faecalibacterium, Collinsella, and Clostridium with the CD4/CD8 ratio, and Faecalibacterium, Ruminococcus, and Dorea with cytokines such as IL-4, and a 20-genus classifier separated patients from controls with AUCs of approximately 0.81 (initial TB) and 0.72 (recurrent TB).
What Are the Implications?
These associations suggest that progressive gut dysbiosis in TB tracks with declining cellular immunity and altered cytokine balance, and that fecal microbiome signatures may have potential as adjunctive, non-invasive markers to help distinguish disease stages. Because the design is cross-sectional, causality cannot be inferred, and although recent antibiotic and probiotic use was excluded, residual confounding from disease severity and treatment cannot be ruled out. The findings are hypothesis-generating and require longitudinal and mechanistic validation, including in independent cohorts, before any diagnostic or microbiome-modulating therapeutic application in TB.